Bengt Åke Ingemar Aldén
Amministratore Delegato presso Aldenco AB
Profilo
Bengt Åke Ingemar Aldén is the founder of Limone AB.
He currently holds the position of President & Chief Executive Officer at Aldenco AB since 2013 and is also the Chairman of IsiFer AB.
In the past, he has served as Chairman of Apreamare SpA, Moberg Pharma AB, Aprea Therapeutics AB, Promore Pharma AB, Xspray Pharma AB, Akinion Pharmaceuticals AB, and AnaMar AB.
He has also worked as a Director at Axelar AB and ClanoTech AB.
Additionally, he has held positions as a Principal at Merck & Co., Inc., Hoechst AG, Hoechst Marion Roussel, Inc., and Astra Pharmaceuticals, Inc.
Posizioni attive di Bengt Åke Ingemar Aldén
| Società | Posizione | Inizio |
|---|---|---|
| IsiFer AB | Presidente | 14/07/2009 |
| Aldenco AB | Amministratore Delegato | - |
Precedenti posizioni note di Bengt Åke Ingemar Aldén
| Società | Posizione | Fine |
|---|---|---|
| MOBERG PHARMA AB | Presidente | 22/04/2010 |
| Hoechst Marion Roussel, Inc. | Corporate Officer/Principal | - |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Presidente | - |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | - |
Limone AB
 Limone AB Pharmaceuticals: MajorHealth Technology Limone is developing new treatments for cancer. The target is the protein LL37 recently reported to act as a growth factor for cancer cells in various cancer indications. Limone has a patent estate covering LL37 and is actively looking for a partner to develop this therapeutic concept. | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| MOBERG PHARMA AB | Health Technology |
| Aziende private | 13 |
|---|---|
Apreamare SpA
 Apreamare SpA Recreational ProductsConsumer Durables Apreamare SpA is a manufacturer of shipping boats and yachts. They also sell new and pre-owned models of their products. The company was founded in 1983 and is headquartered in Torre Annunziata, Italy. | Consumer Durables |
| Astra Pharmaceuticals, Inc. | |
AnaMar AB
 AnaMar AB Pharmaceuticals: MajorHealth Technology AnaMar AB develops drugs and provides research services for chronic joint diseases. It focuses on the discovery, development and commercialization of novel therapeutic strategies to treat debilitating inflammation and pain. The company was founded in 1998 and is headquartered in Lund, Sweden. | Health Technology |
Promore Pharma AB
 Promore Pharma AB BiotechnologyHealth Technology Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden. | Health Technology |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
| IsiFer AB | |
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Health Technology |
Limone AB
Limone AB Pharmaceuticals: MajorHealth Technology Limone is developing new treatments for cancer. The target is the protein LL37 recently reported to act as a growth factor for cancer cells in various cancer indications. Limone has a patent estate covering LL37 and is actively looking for a partner to develop this therapeutic concept. | Health Technology |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
| Aldenco AB | |
| Hoechst Marion Roussel, Inc. |
- Borsa valori
- Insiders
- Bengt Åke Ingemar Aldén
